Meeting
2019 Genitourinary Cancers Symposium
Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction.
Authors
Ashish M. Kamat
The University of Texas MD Anderson Cancer Center, Houston, TX
Ashish M. Kamat , Neal D. Shore , Noah M. Hahn , Shaheen Alanee , Hiroyuki Nishiyama , Shahrokh Shariat , Kijoeng Nam , Ekta Kapadia , Tara L. Frenkl , Gary D. Steinberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT03711032
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS502)
DOI
10.1200/JCO.2019.37.7_suppl.TPS502
Abstract #
TPS502
Poster Bd #
N12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin unresponsive high-risk non-muscle invasive bladder cancer: CREST Study Cohort B.
First Author: Neal D. Shore
Poster
2019 ASCO Annual Meeting
Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.
First Author: Ashish M. Kamat
Poster
2016 ASCO Annual Meeting
KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC).
First Author: Ashish M. Kamat
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
First Author: Neal D. Shore